Seres Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Seres Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Debt, after subtracting cash, is 1.7 times its market value (net debt). Lower than 96% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-30.8×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 65% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 3/3Sales grew in 1 of the last 3 years; profit grew in 3 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
0.1×Debt due within a year is covered 0.1 times by its yearly operating cash.
Higher than 69% of Healthcare companies in United States.
Cash Cushion Ratio
1.7× debtDebt, after subtracting cash, is 1.7 times its market value (net debt).
Lower than 96% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Seres Therapeutics, Inc. made a loss over the last year. Seres Therapeutics, Inc. owes $0.66 for every $1 it owns. Net profit rose 4088% in the year to Dec 2025.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossSeres Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.62The share price is 0.62 times Seres Therapeutics, Inc.'s book value per share, lower than 88% of Healthcare companies in United States.
Market cap
$21 MThe total market value of all of Seres Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 82% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$35 MWhat Seres Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$3.44Net worth divided by the number of shares. The share price of $2.13 is 0.6 times this, which is the P/B above.
Return on equity (ROE)
-66.6%Seres Therapeutics, Inc. lost 66.6% of its shareholders' money over the last year, lower than 60% of Healthcare companies in United States.
Owes vs Owns
0.66×Seres Therapeutics, Inc. owes $0.66 for every $1 it owns (moderate), higher than 69% of Healthcare companies in United States.
Dividend yield
NoneSeres Therapeutics, Inc. does not currently pay a dividend.
Profit growth
+4088%Net profit rose 4088% in the year to Dec 2025.
Profit margin
721.9%Seres Therapeutics, Inc. keeps $722 of every $100 of revenue as net profit.
Cash quality
0.2×Cash from Seres Therapeutics, Inc.'s business was 0.2× its reported profit in the year to Dec 2025 — less cash came in than the profit reported.
Cash vs debt
Net debtSeres Therapeutics, Inc. had $37 M more debt than cash (net debt) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Seres Therapeutics, Inc.: $21 M ÷ $35 M (30 Jun 2026) = 0.6.
What is Seres Therapeutics, Inc.'s return on equity?
Seres Therapeutics, Inc. lost 66.6% of its shareholders' money over the last year, lower than 60% of Healthcare companies in United States.
How much does Seres Therapeutics, Inc. owe compared with what it owns?
Seres Therapeutics, Inc. owes $0.66 for every $1 it owns (moderate), higher than 69% of Healthcare companies in United States.
Does Seres Therapeutics, Inc. pay a dividend?
No. Seres Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.